Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors.
FRET
FlipGFP
ITC
SARS-CoV-2 3CLpro
Journal
Chemical biology & drug design
ISSN: 1747-0285
Titre abrégé: Chem Biol Drug Des
Pays: England
ID NLM: 101262549
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
26
06
2023
received:
21
05
2023
accepted:
07
07
2023
medline:
13
9
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
ppublish
Résumé
SARS-CoV-2 chymotrypsin-like cysteine protease (3CL
Substances chimiques
Isatin
82X95S7M06
Protease Inhibitors
0
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
857-869Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Anand, K., Palm, G. J., Mesters, J. R., Siddell, S. G., Ziebuhr, J., & Hilgenfeld, R. (2002). Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. The EMBO Journal, 21(13), 3213-3224.
Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003). Coronavirus main proteinase (3clpro) structure: Basis for design of anti-sars drugs. Science, 300(5626), 1763-1767.
Chen, L. R., Wang, Y. C., Lin, Y. W., Chou, S. Y., Chen, S. F., Liu, L. T., Wu, Y. T., Kuo, C. J., Chen, T. S., & Juang, S. H. (2005). Synthesis and evaluation of isatin derivatives as effective sars coronavirus 3cl protease inhibitors. Bioorganic & Medicinal Chemistry Letters, 15(12), 3058-3062.
Chen, Y., Liu, Q., & Guo, D. (2020). Emerging coronaviruses: Genome structure, replication, and pathogenesis. Journal of Medical Virology, 92(4), 418-423.
Corman, V. M., Muth, D., Niemeyer, D., & Drosten, C. (2018). Hosts and sources of endemic human coronaviruses. Advances in Virus Research, 100, 163-188.
Forni, D., Cagliani, R., Clerici, M., & Sironi, M. (2017). Molecular evolution of human coronavirus genomes. Trends in Microbiology, 25(1), 35-48.
Fu, L., Shao, S., Feng, Y., Ye, F., Sun, X., Wang, Q., Yu, F., Wang, Q., Huang, B., Niu, P., Li, X., Wong, C. C. L., Qi, J., Tan, W., & Gao, G. F. (2021). Mechanism of microbial metabolite leupeptin in the treatment of covid-19 by traditional Chinese medicine herbs. MBio, 12(5), e0222021.
Fu, L., Ye, F., Feng, Y., Yu, F., Wang, Q., Wu, Y., Zhao, C., Sun, H., Huang, B., Niu, P., Song, H., Shi, Y., Li, X., Tan, W., Qi, J., & Gao, G. F. (2020). Both boceprevir and gc376 efficaciously inhibit sars-cov-2 by targeting its main protease. Nature Communications, 11(1), 4417.
Gao, K., Wang, R., Chen, J., Tepe, J. J., Huang, F., & Wei, G. W. (2021). Perspectives on sars-cov-2 main protease inhibitors. Journal of Medicinal Chemistry, 64(23), 16922-16955.
Gerber, P. P., Duncan, L. M., Greenwood, E. J., Marelli, S., Naamati, A., Teixeira-Silva, A., Crozier, T. W., Gabaev, I., Zhan, J. R., Mulroney, T. E., Horner, E. C., Doffinger, R., Willis, A. E., Thaventhiran, J. E., Protasio, A. V., & Matheson, N. J. (2022). A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection. PLoS Pathogens, 18(2), e1010265.
Grum-Tokars, V., Ratia, K., Begaye, A., Baker, S. C., & Mesecar, A. D. (2008). Evaluating the 3c-like protease activity of sars-coronavirus: Recommendations for standardized assays for drug discovery. Virus Research, 133(1), 63-73.
Hoffman, R. L., Kania, R. S., Brothers, M. A., Davies, J. F., Ferre, R. A., Gajiwala, K. S., He, M., Hogan, R. J., Kozminski, K., Li, L. Y., Lockner, J. W., Lou, J., Marra, M. T., Mitchell, L. J., Jr., Murray, B. W., Nieman, J. A., Noell, S., Planken, S. P., Rowe, T., … Taggart, B. (2020). Discovery of ketone-based covalent inhibitors of coronavirus 3cl proteases for the potential therapeutic treatment of covid-19. Journal of Medicinal Chemistry, 63(21), 12725-12747.
Hsu, M. F., Kuo, C. J., Chang, K. T., Chang, H. C., Chou, C. C., Ko, T. P., Shr, H. L., Chang, G. G., Wang, A. H., & Liang, P. H. (2005). Mechanism of the maturation process of sars-cov 3cl protease. The Journal of Biological Chemistry, 280(35), 31257-31266.
Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., Duan, Y., Yu, J., Wang, L., Yang, K., Liu, F., Jiang, R., Yang, X., You, T., Liu, X., … Yang, H. (2020). Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature, 582(7811), 289-293.
Ma, C., Tan, H., Choza, J., Wang, Y., & Wang, J. (2022). Validation and invalidation of sars-cov-2 main protease inhibitors using the flip-gfp and protease-glo luciferase assays. Acta Pharmaceutica Sinica B, 12(4), 1636-1651.
Ma, C., Sacco, M. D., Xia, Z., Lambrinidis, G., Townsend, J. A., Hu, Y., Meng, X., Szeto, T., Ba, M., Zhang, X., Gongora, M., Zhang, F., Marty, M. T., Xiang, Y., Kolocouris, A., Chen, Y., & Wang, J. (2021). Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay. ACS Central Science, 7(7), 1245-1260.
Pawelczak, M., & Hurek, J. (2014). Enzymatic slow-binding inhibition. Chem, 68, 381-384.
Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y., & Jung, S. H. (2016). An overview of severe acute respiratory syndrome-coronavirus (sars-cov) 3cl protease inhibitors: Peptidomimetics and small molecule chemotherapy. Journal of Medicinal Chemistry, 59(14), 6595-6628.
Tripathi, P. K., Upadhyay, S., Singh, M., Raghavendhar, S., Bhardwaj, M., Sharma, P., & Patel, A. K. (2020). Screening and evaluation of approved drugs as inhibitors of main protease of sars-cov-2. International Journal of Biological Macromolecules, 164, 2622-2631.
Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., Hu, Y., Tao, Z. W., Tian, J. H., Pei, Y. Y., Yuan, M. L., Zhang, Y. L., Dai, F. H., Liu, Y., Wang, Q. M., Zheng, J. J., Xu, L., Holmes, E. C., & Zhang, Y. Z. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265-269.
Xia, Z., Sacco, M., Hu, Y., Ma, C., Meng, X., Zhang, F., Szeto, T., Xiang, Y., Chen, Y., & Wang, J. (2021). Rational design of hybrid sars-cov-2 main protease inhibitors guided by the superimposed cocrystal structures with the peptidomimetic inhibitors gc-376, telaprevir, and boceprevir. ACS Pharmacology & Translational Science, 4(4), 1408-1421.
Xiong, M., Su, H., Zhao, W., Xie, H., Shao, Q., & Xu, Y. (2021). What coronavirus 3c-like protease tells us: From structure, substrate selectivity, to inhibitor design. Medicinal Research Reviews, 41(4), 1965-1998.
Xu, Y., Chen, K., Pan, J., Lei, Y., Zhang, D., Fang, L., Tang, J., Chen, X., Ma, Y., Zheng, Y., Zhang, B., Zhou, Y., Zhan, J., & Xu, W. (2021). Repurposing clinically approved drugs for covid-19 treatment targeting sars-cov-2 papain-like protease. International Journal of Biological Macromolecules, 188, 137-146.
Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., Gao, G. F., Anand, K., Bartlam, M., Hilgenfeld, R., & Rao, Z. (2003). The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 100(23), 13190-13195.
Yi, Y., Zhang, M., Xue, H., Yu, R., Bao, Y. O., Kuang, Y., Chai, Y., Ma, W., Wang, J., Shi, X., Li, W., Hong, W., Li, J., Muturi, E., Wei, H., Wlodarz, J., Roszak, S., Qiao, X., Yang, H., & Ye, M. (2022). Schaftoside inhibits 3cl(pro) and pl(pro) of sars-cov-2 virus and regulates immune response and inflammation of host cells for the treatment of covid-19. Acta Pharmaceutica Sinica B, 12, 4154-4164.
Zhang, Q., Schepis, A., Huang, H., Yang, J., Ma, W., Torra, J., Zhang, S. Q., Yang, L., Wu, H., Nonell, S., Dong, Z., Kornberg, T. B., Coughlin, S. R., & Shu, X. (2019). Designing a green fluorogenic protease reporter by flipping a beta strand of gfp for imaging apoptosis in animals. Journal of the American Chemical Society, 141(11), 4526-4530.
Zhang, S., Wang, J., & Cheng, G. (2021). Protease cleavage of RNF20 facilitates coronavirus replication via stabilization of SREBP1. Proceedings of the National Academy of Sciences, 118(37), e2107108118.